UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 98

Sortiert nach

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

Oncogene, 2021-10, Vol.40 (40), p.5893-5901

2021

Link zum Volltext

Verfügbarkeit prüfen

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway

PPAR Research, 2017-01, Vol.2017, p.8187235-15

2017

Link zum Volltext

Verfügbarkeit prüfen

The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer

PPAR Research, 2017-01, Vol.2017, p.1830626-2

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

Oncoimmunology, 2019-04, Vol.8 (4), p.e1561120-e1561120

2019

Link zum Volltext

Verfügbarkeit prüfen

Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions

PPAR Research, 2016-01, Vol.2016, p.6517313-9

2016

Link zum Volltext

Verfügbarkeit prüfen

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

Oncotarget, 2016-09, Vol.7 (37), p.60712-60722

2016

Link zum Volltext

Verfügbarkeit prüfen

MUTYH-associated tumor syndrome: The other face of MAP

Oncogene, 2022-04, Vol.41 (18), p.2531-2539

2022

Link zum Volltext

Verfügbarkeit prüfen

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Oncoimmunology, 2020-01, Vol.9 (1), p.1832348-1832348

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231151845-17588359231151845

2023

Link zum Volltext

Verfügbarkeit prüfen

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

Cancers, 2020-08, Vol.12 (9), p.2415

2020

Link zum Volltext

Verfügbarkeit prüfen

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

Therapeutic advances in medical oncology, 2019-05, Vol.11, p.1758835919848872-1758835919848872

2019

Link zum Volltext

Verfügbarkeit prüfen

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Oncotarget, 2015-09, Vol.6 (28), p.24780-24796

2015

Link zum Volltext

Verfügbarkeit prüfen

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

Cancers, 2020-11, Vol.12 (11), p.3396

2020

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

Cancers, 2022-09, Vol.14 (18), p.4344

2022

Link zum Volltext

Verfügbarkeit prüfen

PPARs and Mitochondrial Metabolism: From NAFLD to HCC

PPAR Research, 2016-01, Vol.2016, p.7403230-18

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?

Cancers, 2021-04, Vol.13 (9), p.2118

2021

Link zum Volltext

Verfügbarkeit prüfen

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes

Cancers, 2020-05, Vol.12 (5), p.1158

2020

Link zum Volltext

Verfügbarkeit prüfen

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920975326-1758835920975326

2020

Link zum Volltext

Verfügbarkeit prüfen

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

International journal of molecular sciences, 2017-05, Vol.18 (5), p.1100

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

Frontiers in oncology, 2021-06, Vol.11, p.682445-682445

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

Frontiers in oncology, 2022-02, Vol.12, p.827822-827822

2022

Link zum Volltext

Verfügbarkeit prüfen

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma

Oncotarget, 2018-07, Vol.9 (56), p.30837-30846

2018

Link zum Volltext

Verfügbarkeit prüfen

BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?

Frontiers in oncology, 2024-06, Vol.14, p.1414343

2024

Link zum Volltext

Verfügbarkeit prüfen

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

Frontiers in oncology, 2022-09, Vol.12, p.946319-946319

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(98)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway

The Interplay between Metabolism, PPAR Signaling Pathway, and Cancer

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

MUTYH-associated tumor syndrome: The other face of MAP

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer

PPARs and Mitochondrial Metabolism: From NAFLD to HCC

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength

Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma

BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

Suchergebnisse filtern